Did the critics of Acadia Pharmaceuticals — and I’m very much included in that group — underestimate the efficacy of the drugmaker’s antipsychotic medicine Nuplazid? Or, did we fail to appreciate Acadia’s cleverness in designing a clinical trial for a mediocre medicine that could still deliver a positive result?

Maybe I’m stubborn, but I lean towards the latter. Still, there is no denying that Monday is a very good day for Acadia and those who believe in Nuplazid’s potential to be a more widely used antipsychotic drug. A Phase 3 clinical trial investigating Nuplazid as a treatment for dementia-related psychosis was stopped early for positive efficacy, Acadia announced.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • hi Adam
    are you generally against enrichment trials (if that’s what it could be called)? i understand your point about sedation – may as well use haloperidol if that is the main effect as there seems to be an issue with prolonging QT of combination products as well. if most (75% plus?) of the patients responded in the run-up part of the trial and entered the blinded phase (though i suppose difficult to be blinded if the placebo isn’t sedating) then that would be ok wouldn’t it? if they lost more than 50% in the run-up, that would suggest a niche product at best. I suppose the data need to be published…..

  • Let’s imagine that early criticism of the clinical trial were to have enough widespread reading so as to collapse the stock price and prevent further development of the drug (resulting inability to raise capital). Let’s also assume that this positive news is real. That means patients would suffer by not having access to a drug that would have otherwise continued development.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy